Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 17/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 17/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.75 |
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.59 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.59 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242329 | 0.90 | ADORA2B (0.75) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL243375 | 0.88 | ADORA2B (0.74) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL243438 | 0.87 | ADORA2B (0.79) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1546818 | 0.86 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1546037 | 0.83 | ADORA2B (0.84) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1948145 | 0.77 | ADORA2B (0.77) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL243681 | 0.77 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1944742 | 0.77 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1546069 | 0.76 | ADORA2A (1.00) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1947425 | 0.76 | ADORA2A (1.00) | ADORA2BADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595630-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | Gilead Sciences, Inc. (US) | 2013-05-29 | — | — | EP | claimed |
| EP-1789053-B1 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES INC (US) | 2012-06-13 | — | — | EP | claimed |
| US-20120003329-A1 | Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension | GILEAD SCIENCES, INC. | 2012-01-05 | — | — | US | claimed |
| WO-2012003220-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | claimed |
| US-20100105706-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO, INC. (US) | 2010-04-29 | — | — | US | claimed |
| EP-1622908-B1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1799221-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-06-27 | — | — | EP | claimed |
| EP-1789053-A2 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-05-30 | — | — | EP | claimed |
| US-20060159627-A1 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-07-20 | — | — | US | claimed |
| WO-2006044610-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2006028810-A2 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-03-16 | — | — | US | claimed |
| EP-1622908-A1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-02-08 | — | — | EP | claimed |
| US-6977300-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2005-12-20 | — | — | US | claimed |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-24 | — | — | US | claimed |
| WO-2004106337-A1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | WO | claimed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | claimed |
| EP-3103454-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | Gilead Sciences, Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20040176399-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2004-09-09 | — | — | US | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003329-A1 | Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension | ADORA2B, ADORA2A, TBXA2R | ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20100105706-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20040176399-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.